BIOLOGICAL · Unmapped registry intervention
Anti-GM-CSF Monoclonal Antibody 400mg
Find medicine records ·
Find other trials using this name
Clinical trial
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
NCT01603277
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedEffect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Moderate-to-Severe Asthmaunresolved
Interventions
Anti-GM-CSF Monoclonal Antibody 400mgBIOLOGICAL
PlaceboOTHER
Sponsors & collaborators
Humanigen, Inc.lead sponsor
Mapped research locations
MiamiFlorida, United States2Oklahoma CityOklahoma, United States2CharlestonSouth Carolina, United States2KrakowPoland2Los AngelesCalifornia, United States1St LouisMissouri, United States1BirminghamAlabama, United States1TampaFlorida, United States1DenverColorado, United States1Ann ArborMichigan, United States1Winston-SalemNorth Carolina, United States1SacramentoCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01603277 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.